127 related articles for article (PubMed ID: 38598583)
1. Selpercatinib and Pseudo-Decreases in Kidney Function.
Izzedine H; Bouderlique E; Besse B
N Engl J Med; 2024 Apr; 390(13):1241-1243. PubMed ID: 38598583
[No Abstract] [Full Text] [Related]
2. Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.
Szymczak S; Szpurka A; Lu ZH; Dempsey JA
Thyroid; 2023 Dec; 33(12):1493-1495. PubMed ID: 37376747
[No Abstract] [Full Text] [Related]
3. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.
Sarvestani AL; Lambdin J; Hu M; Cabanillas M; Waguespack SG; Hernandez JM; Zafereo ME
Ann Surg Oncol; 2024 Apr; 31(4):2202-2203. PubMed ID: 38245643
[No Abstract] [Full Text] [Related]
4. Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
Della Corte CM; Morgillo F
ESMO Open; 2021 Feb; 6(1):100041. PubMed ID: 33477006
[No Abstract] [Full Text] [Related]
5. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
6. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
8. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
9. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Subbiah V; Shen T; Tetzlaff M; Weissferdt A; Byers LA; Cascone T; Behrang A; Meric-Bernstam F; Mooers BHM; Rothenberg SM; Ebata K; Wu J
Ann Oncol; 2021 Jun; 32(6):817-819. PubMed ID: 33617938
[No Abstract] [Full Text] [Related]
10. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
11. Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer.
Larkin HD
JAMA; 2022 Nov; 328(17):1679. PubMed ID: 36318150
[No Abstract] [Full Text] [Related]
12. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
Schrenk KG; Weschenfelder W; Spiegel C; Agaimy A; Stöhr R; Hartmann A; Gaßler N; Drescher R; Freesmeyer M; Malouhi A; Bürckenmeyer F; Aschenbach R; Teichgräber U; Kögler C; Vogt M; Hofmann GO; Hochhaus A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5493-5496. PubMed ID: 36469155
[TBL] [Abstract][Full Text] [Related]
13. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander EM; Shah MH; Zhou Y; Goyal A; Palmer JD; Owen DH; Shilo K; Patel G; Raval RR; Gonzalez J; Nguyen M; Olek E; Kherani J; Rothenberg SM; Konda B
Clin Lung Cancer; 2021 May; 22(3):e442-e445. PubMed ID: 32660930
[No Abstract] [Full Text] [Related]
14. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
15. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
17. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
18. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
19. Determination of selpercatinib, a RET kinase inhibitor, in rat plasma and its application to a pharmacokinetic study.
Wang W; Shi L; Jin L; Wang K
Biomed Chromatogr; 2021 May; 35(5):e5052. PubMed ID: 33314236
[TBL] [Abstract][Full Text] [Related]
20. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]